Why Memory Deteriorates After Stroke?
Post-stroke cognitive impairment presents with diverse and often insidious symptoms. Memory decline is the most common manifestation, wherein patients exhibit difficulty recalling recent events, such as a recently consumed meal or a newly encountered individual; in severe cases, they may even forget personal identity information or daily routines. Some patients develop language expression difficulties, characterized by anomia, paraphasias, repetitive speech, or an inability to articulate complete thoughts.
On June 21, 2025, Professor Yi Xie and Professor Xinfeng Liu from Nanjing University School of Medicine published research in Cell Reports titled: "Lipocalin-2 regulates astrocyte-oligodendrocyte interaction to drive post-stroke secondary demyelination." Their study reveals that Lipocalin-2 (LCN2) drives post-stroke secondary demyelination by regulating the interaction between astrocytes and oligodendrocytes.
Products
At Creative Biolabs, we offer a wide range of products and services to fuel your neuroscience research. Please contact us for more information.
Cat. No | Product Name | Product Types |
---|---|---|
NCL-21P6-082 | Mouse Microglia from C57BL/6 | Primary cells |
NRP-0322-P2266 | iNeu™ Human Microglia | iPSC-derived cells |
NCL-21P6-083 | Rat Microglia | Primary cells |
NCL2110P028 | Mouse Oligodendrocytes | Primary cells |
NRZP-1122-ZP183 | Human Oligodendrocytes | Primary cells |
NRZP-1122-ZP220 | Rat Oligodendrocytes | Primary cells |
NCL-2103-P49 | iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) | iPSC-derived cells |
Services | Description |
---|---|
Microglia related Assay Services | Microglial assays are essential tools for researchers studying immune responses, pathological processes, neural development, and inflammatory mechanisms within the central nervous system (CNS). This research forms a vital scientific basis for diagnosing and treating neurological diseases. Creative Biolabs performs all microglial assays using primary mouse microglia (wild-type and disease models), human primary microglia, or human iPSC-derived microglia. |
Oligodendrocyte Precursor Cell (OPC) related Assay Service | Oligodendrocyte precursor cells (OPCs) are crucial to the central nervous system (CNS). While best known for their essential role in myelination, OPCs also contribute significantly to neural development, regeneration, angiogenesis, and immune regulation. At Creative Biolabs, we provide comprehensive OPC assays using primary mouse OPCs (wild-type and disease models), human primary OPCs, and human iPSC-derived OPCs. |
Overview
The specific involvement of oligodendrocytes in this process has remained ill-defined. To elucidate this, a distal middle cerebral artery occlusion (dMCAO) model was established in mice. By seven days post-injury, Lipocalin-2 (LCN2) was observed to partially disseminate from the infarct-adjacent corpus callosum into the contralateral hemisphere. Concurrently, in reactive astrocytes of the contralateral corpus callosum, LCN2 exhibited significant upregulation at both transcriptional and translational levels.
Further investigation elucidated that PERK-mediated endoplasmic reticulum stress drove the activation of these contralateral astrocytes, leading to their autonomous synthesis of LCN2. Subsequently, mature oligodendrocytes internalized this LCN2, which precipitated the degeneration of their cellular processes and induced apoptosis. Astrocyte-specific knockout of the Lcn2 gene attenuated oligodendrocyte loss, demyelination, and cognitive dysfunction after cerebral infarction; conversely, astrocyte-specific overexpression of LCN2 reversed these beneficial effects. Mechanistic studies indicated that this LCN2-induced myelin damage likely involves a physical interaction with low-density lipoprotein receptor-related protein 2 (LRP2) on oligodendrocytes, which then activates the JNK3 signaling pathway. Specific knockdown of Lrp2 ameliorated LCN2-induced oligodendrocyte damage.
The authors' findings demonstrate that reactive astrocytes regulate post-stroke secondary demyelination via the LCN2-LRP2 signaling pathway, uncovering a novel intercellular pathogenic axis. This provides crucial insights into the mechanisms of white matter injury after cerebral infarction and offers a potential direction for developing targeted therapeutic strategies.
Findings of the Study
In summary, the authors have elucidated the mechanism of interaction between astrocytes and oligodendrocytes during distal white matter injury following focal ischemic stroke. Their findings demonstrate that modulating this intercellular communication can effectively mitigate demyelination. Specifically, endoplasmic reticulum stress, sensed by PERK, prompts reactive astrocytes to release substantial amounts of Lipocalin-2 (LCN2) extracellularly. Subsequently, mature oligodendrocytes internalize LCN2 via the expression of low-density lipoprotein receptor-related protein 2 (LRP2), which in turn activates the JNK3/c-Jun signaling pathway, leading to oligodendrocyte dysfunction or even apoptosis. This research provides a theoretical basis and potential interventional strategies for treating neurovascular diseases involving white matter lesions, by targeting either secreted LCN2 or its downstream receptor LRP2.
Disclaimer: Please note that we do not provide the content above, nor do we hold copyright to it. This article is for informational and knowledge-sharing purposes only and does not constitute an offer of commercial services related to its subject matter.
Resources
Reference
- Huang, Zhenqian et al. "Lipocalin-2 regulates astrocyte-oligodendrocyte interaction to drive post-stroke secondary demyelination." Cell reports, vol. 44,7 115899. 21 Jun. 2025, doi:10.1016/j.celrep.2025.115899. Distributed under Open Access license CC BY 4.0, without modification.
- iNeuMab™ Anti-TREM2 BBB Shuttle Antibody (NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody (NRZP-1222-ZP1218) (Cat#: NRZP-1222-ZP1218)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)